IMPORTANCE Treatment choice for lung squamous cell carcinoma could be aided by identifying predictive biomarkers.
S quamous cell carcinoma (SqCC) of the lung is one of the most genetically complex and difficult-to-treat cancers. 1 Until recently, platinum doublet chemotherapy was the first-line treatment of choice for most patients with lung SqCC, and second-line treatment options were also limited, with erlotinib hydrochloride (an epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) and docetaxel as the only approved options. 2 Recently, several new agents have been approved for patients with lung SqCC, including the EGFR monoclonal antibody necitumumab (combined with standard first-line chemotherapy) 3 and the immune checkpoint inhibitor pembrolizumab (in tumors with high expression levels of programmed cell death ligand 1 [PD-L1]) 4 as firstline treatments. The immune checkpoint inhibitors nivolumab, 5 pembrolizumab, 6 and atezolizumab 7 ; the antivascular endothelial growth factor receptor 2 antibody ramucirumab (combined with docetaxel) 8 ; and the ERBB family blocker afatinib have been approved as second-line treatments. 9 This expansion of the armamentarium invites questions regarding optimal treatment of lung SqCC, which could be addressed by identifying biomarkers that may predict outcomes. Afatinib dimaleate was approved as a second-line treatment of lung SqCC based on the phase 3 LUX-Lung 8 randomized clinical trial, which compared treatment with afatinib vs erlotinib following progression during and after chemotherapy. 9 Compared with erlotinib therapy, treatment with afatinib significantly improved overall survival (OS; median, 7.9 vs 6.8 months; hazard ratio [HR] ; 0.81: 95% CI, 0.69-0.95; P = .008) and progression-free survival (PFS; median, 2.6 vs 1.9 months; HR, 0.81; 95% CI, 0.69-0.96; P = .01). The tolerability profile was similar in both treatment arms and was consistent with prior experience.
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To investigate whether the efficacy of afatinib in lung SqCC varied depending on the molecular characteristics of tumors, we conducted a comprehensive genetic analysis using Foundation Medicine FoundationOne next-generation sequencing (NGS) in a cohort of 245 patients who were included in the LUX-Lung 8 trial. The aims were to (1) assess the genetic characteristics of SqCC tumors in this cohort; (2) identify individual genes that are commonly mutated in this cohort and assess outcomes with respect to these genes; and (3) characterize and calculate the cumulative mutation frequency in the ERBB family of genes, assessing outcomes among patients with tumors with or without such mutations. Previous studies have reported mutation frequencies in EGFR, HER2, HER3, and HER4 of approximately 1% to 3%, 4%, 1% to 2%, and 8%, respectively. [10] [11] [12] [13] Given that afatinib irreversibly inhibits signaling from all homodimers and heterodimers of the ERBB family and that these receptors cooperate via interconnected intracellular pathways to regulate cellular proliferation, 14 it is possible that genetic aberrations within the family might identify a subgroup of patients who could particularly benefit from afatinib treatment. Therefore, analysis of ERBB/HER family aberrations was prespecified in the present analysis. Furthermore, given that up to 80% of lung SqCC tumors overexpress EGFR 15 and that EGFR, HER2, and HER3 amplifications have been reported, 10,13 we assessed outcomes based on EGFR expression levels and ERBB family copy number alterations (CNAs).
Methods

Study, Design, and Participants
The design of the LUX-Lung 8 trial has been previously described. 9 In brief, patients had stage IIIB or IV non-small cell lung cancer (NSCLC) of squamous (including mixed) histologyandhadprogressedduringorafter4ormorecyclesofplati-num-based doublet chemotherapy as a first-line treatment. The included 795 patients were randomized (1:1) to treatment with afatinib (40 mg/d; 398 patients) or erlotinib (150 mg/d; 397 patients), and randomization was stratified by race/ethnicity (East Asian vs non-East Asian origin) to eliminate any potential bias in EGFR mutation frequency. The primary end point was PFS (independent review). The key secondary end point was OS. Tumor specimens and blood samples for exploratory biomarker analysis were required at study entry. The study was conducted in accordance with the Declaration of Helsinki,
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Good Clinical Practice guidelines, and applicable regionspecific regulatory requirements and was approved by independent ethics committees at each center. All patients provided written informed consent. The present study is an ad hoc, retrospective secondary analysis of the LUX-Lung 8 trial. Patients included in LUX-Lung 8 were required to have archival tissue available for investigational assessment of tumor biomarkers. Therefore, collection of tumor samples was preplanned.
Tumor Genetic Analysis
Formalin-fixed, paraffin-embedded tumor specimens were submitted to Foundation Medicine for genetic analysis. The DNA was extracted from sections (40-μm thick) of these specimens obtained from 245 patients. Next-generation sequencing was performed on hybridization-captured, adaptor ligationbased libraries for 4557 coding exons of 287 cancer-related genes, plus 47 introns from 19 genes frequently rearranged in
Key Points
Question What is the association between ERBB family mutations and outcomes of patients with lung squamous cell carcinoma who received treatment with afatinib dimaleate or erlotinib hydrochloride?
Findings In this secondary analysis of the LUX-Lung 8 trial, of 245 clinically selected patients, 21.6% had tumors with at least 1 ERBB mutation. Although progression-free survival and overall survival were improved with afatinib vs erlotinib treatment among patients with ERBB wild-type tumors, this was more pronounced among patients with tumors having at least 1 ERBB family mutation, with the largest benefits observed among those with HER2 mutations.
Meaning Mutations of ERBB, particularly HER2 mutations, may be used as a biomarker to identify patients with lung squamous cell carcinoma who would derive additional benefit from afatinib.
cancer, and 3549 polymorphisms located throughout the genome to detect mutations (single-nucleotide variants), CNAs, and rearrangements. The NGS-based clinical cancer gene assay has been published previously, and the assay performance has been validated. 17 The Foundation Medicine T7 assay used in this study is able to detect mutations in all 4 ERBB receptors (EGFR, HER2, HER3, and HER4), unlike more commonly used circulating tumor DNA platforms, such as Foundation ACT (which detects EGFR alterations only) or Guardant360 (which measures EGFR and HER2 alterations). The specimens for tumor genetic analysis (TGA) were retrospectively selected and enriched for patients with PFS of more than 2 months (149 of 245 patients [60.8%] with specimens used for TGA had PFS of more than 2 months vs 341 of 795 patients [42.9%] in the overall LUX-Lung 8 population) to ensure that the data set reflected a range of responsiveness to EGFR-targeted tyrosine kinase inhibitors (eAppendix in the Supplement).
EGFR Immunohistochemistry
The expression of EGFR was assessed using immunohistochemistry (IHC) with an EGFR pharmDx kit (Dako). Two separate criteria for EGFR positivity, based on definitions from previous studies, 15, 18 were used. For the first criterion, a tumor was considered positive for EGFR if at least 10% of the tumor cells showed staining of any intensity. For the second criterion, a tumor was considered positive for EGFR if the H-score was 200 or greater when using the H-score method with magnification rule, which assigns a score from 0 to 300 to tumor specimens depending on the percentage of positive cells and the intensity of staining.
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Statistical Analysis
The OS and PFS were calculated using the Kaplan-Meier method. A Cox proportional hazards regression model was used to calculate HRs and 95% CIs. All analyses were conducted with SAS, version 9.2 (SAS Institute Inc). Two-sided P < .05 was considered statistically significant.
Results
Patients
The LUX-Lung 8 trial was conducted at 183 centers in 23 countries from March 30, 2012, to January 30, 2014. In total, 977 patients were enrolled and 795 patients were randomized, with 398 in the afatinib arm and 397 in the erlotinib arm ( Figure 1) . Among the 742 patients with archival tumor tissue specimens available, 440 specimens were selected for TGA (PFS >2 months, 320 specimens; PFS ≤2 months, 120 specimens). Of these specimens, 195 were ineligible for NGS; thus, the TGA Figure 2 correlates the distribution of genetic aberrations detected in the TGA cohort with the findings previously reported by The Cancer Genome Atlas (TCGA) Research Network, which analyzed tumor specimens from 178 patients with lung SqCC. 12 Overall, the genetic characteristics of SqCC tumors in the TGA cohort were similar to those in the TCGA analysis, although the mutation frequency of certain genes, including KMT2A, KMT2D, FAT3, and CDKN2A, was higher than that in the TCGA study. In the TGA cohort, both PFS (median, 3.5 vs 2.5 months; HR, 0.69; 95% CI, 0.51-0.92; P = .01) and OS (median, 8.4 vs 6.6 months; HR, 0.81; 95% CI, 0.62-1.05; P = .12) favored treatment with afatinib over erlotinib, with systematically lower HRs and longer median PFS and OS than those observed in the overall LUX-Lung 8 population (eFigure 1 in the Supplement). This finding reflects the selection of a high proportion of specimens from patients with PFS of more than 2 months. Therefore, HRs in subgroups should be interpreted relative to the HR in the TGA cohort and not the overall LUX-Lung 8 population (eAppendix in the Supplement). None of the most frequently observed aberrations identified by TGA predicted PFS or OS benefit with afatinib over erlotinib treatment (eFigure 2 in the Supplement).
Tumor Genetic Analysis
Outcomes Among Patients With ERBB Mutation-Positive Tumors
Overall, 53 of 245 patients (21.6%) had tumors with at least 1 ERBB family mutation (Table) . Of 245 patients, 1 patient (0.4%) had tumors with EGFR, HER2, and HER3 mutations, and 2 patients (0.8%) had tumors with HER3 and HER4 mutations. Sixteen patients (6.5%) had tumors with at least 1 EGFR mutation; only 7 of the 17 EGFR mutations detected had previously been described (L861Q, E114K, Q1021, E746, A750del, V843I, and L858R). No tumor tested positive for EGFR variant III mutations, although such mutations are detectable using the Foundation Medicine NGS assay. The HER2 mutations were detected in tumors from 12 patients (4.9%), HER3 mutations in 15 patients (6.1%), and HER4 mutations in 14 patients (5.7%). Two patients (0.8%) had both a HER3 and a HER4 mutation. One patient (0.4%) had an EGFR, a HER3, and a HER4 mutation. Four of the 16 HER3 mutations (P1212S, R103H, and V104L in 2 patients) and 1 of the HER4 mutations (D931Y) have been previously described. Details of the ERBB mutation-positive tumors and the location of the HER2 mutations (detected in both the intracellular and extracellular domains) are shown in eFigure 3 in the Supplement.
In the overall LUX-Lung 8 data set of 398 patients, 21 patients (5.3%) were long-term responders to treatment with afatinib (received ≥12 months of treatment). Ten of these patients were in the TGA cohort, among whom 5 (50.0%) had ERBB mutation-positive tumors (Table) . Therefore, the frequency of ERBB mutation-positive tumors was nominally higher among long-term responders than among the overall afatinib-treated population.
For patients receiving afatinib, both PFS and OS were longer among patients with ERBB mutation-positive tumors than 
KMT2A
The m = 1 line shows the theoretical line on which all points would lie if the frequencies in both studies were identical. a Three patients were long-term responders to erlotinib: 1 patient had a tumor with an EGFR mutation, and 2 patients had tumors that were ERBB wild type.
among those without (PFS: median, 4.9 vs 3.0 months; HR, 0.62; 95% CI, 0.37-1.02; P = .06; OS: median, 10.6 vs 8.1 months; HR, 0.75; 95% CI, 0.47-1.17; P = .21) (Figure 3) . By contrast, in the erlotinib arm, PFS and OS were similar among patients with tumors with or without ERBB mutations (PFS: median, 2.7 vs 2.4 months; HR, 0.76; 95% CI, 0.46-1.26; P = .29; OS: median, 7.2 vs 6.4 months; HR, 0.84; 95% CI, 0.54-1.32; P = .46).
Outcomes assessed with respect to individual ERBB gene family members (Figure 4) indicated that EGFR mutations, in isolation, did not predict PFS or OS benefit of treatment with afatinib over erlotinib; indeed, the accentuated benefit of treatment with afatinib over erlotinib among patients with ERBB mutation-positive tumors appeared to be driven by HER3, HER4, and, in particular, HER2. Among the 12 patients with tumors having a HER2 mutation, PFS (HR, 0.06; 95% CI, 0.01-0.59; P =.02) and OS (HR, 0.06; 95% CI, 0.01-0.57; P = .02) strongly favored treatment with afatinib vs erlotinib. This observation was further underpinned by standardized effect plots (eFigure 4 in the Supplement). Despite the small sample size, the interaction P values were significant for PFS (P = .006) and OS (P = .003), indicating that the presence of a HER2 mutation may predict better outcomes with afatinib vs erlotinib treatment.
Outcomes According to ERBB CNAs
Seventeen (6.9%) and 9 (3.7%) of 245 patients had tumors with CNAs in EGFR and HER2, respectively. No CNA was detected in HER3 or HER4. There was no apparent correlation between CNAs and outcomes among patients treated with afatinib or erlotinib (data not shown).
Outcomes According to EGFR Overexpression
Outcomes in the IHC cohort (n = 345) were similar to those in the overall LUX-Lung 8 data set (PFS: median, 2.0 vs 1.9 months; HR, 0.74; 95% CI, 0.58-0.95; P = .14; OS: median, 7.4 vs 6.6 months; HR, 0.79; 95% CI, 0.63-0.99; P = .04). EGFR overexpression (by either method) did not predict PFS or OS benefit with afatinib vs erlotinib treatment (eTable 3 in the Supplement).
Discussion
To our knowledge, this secondary analysis of the LUX-Lung 8 trial represents the largest and most detailed evaluation of genetic mutations among patients with lung SqCC. Tumors were selected for analysis with Foundation Medicine NGS 17 from 245 patients whose baseline demographic and clinical characteristics were similar to those in the overall LUX-Lung 8 population. Because afatinib is an ERBB family blocker and because other ERBB family members have been implicated in the pathogenesis of lung SqCC, 12,20 the focus of this study was to assess outcomes among patients with ERBB mutation-positive tumors vs those with ERBB wild-type tumors. Although aberrations among individual ERBB family members were rare, cumulatively, 53 of the 245 patients (21.6%) had tumors with mutations in at least 1 ERBB family member. Although PFS and OS benefit with afatinib over erlotinib treatment was apparent among patients with ERBB wild-type tumors, the effects were more pronounced among patients with tumors that had at least 1 ERBB family 
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mutation. Accentuated benefit with afatinib treatment did not appear to be driven by EGFR mutations; indeed, the largest benefits were observed among patients with tumors having HER2 or HER4 mutations. Given the molecular heterogeneity of lung SqCC and the expanding armamentarium of available agents in this setting along with the ability of afatinib to irreversibly inhibit signaling via all ERBB heterodimers and homodimers, the present hypothesis-generating results suggest that identification of mutations in any ERBB family member might identify a subgroup of patients who may particularly benefit from treatment with afatinib following the failure of chemotherapy. Therefore, the role of HER2 as a potential biomarker warrants further investigation. Although HER2 mutations are rare, afatinib has previously demonstrated activity in heavily pretreated patients with adenocarcinoma NSCLC whose tumors had such a mutation. 21 Notably, the pattern of HER2 mutations in the present study was different from that observed in adenocarcinoma NSCLC, in which the most frequently occurring mutations are in-frame insertion alleles in exon 20. 22 In squamous disease, HER2 mutations are individually rarer and more heterogeneously distributed. In the present study, only 2 of the 9 mutations (Q57R and P489L) identified in tumors derived from afatinib-treated patients occurred in more than 1 patient, with 7 of the mutations being detected in the extracellular domain of HER2 and only 2 mutations occurring in the intracellular domain (G815R and P1037L The present study assessed the broad genetic characteristics of SqCC tumors in a large number of patients, potentially providing insights into the molecular pathogenesis of the disease. We found that the prevalence of the molecular aberrations in the LUX-Lung 8 population was consistent with data reported by the TCGA. 12 The higher mutation frequencies observed in certain genes in the LUX-Lung 8 population (KMT2A, KMT2D, FAT3, and CDKN2A) may be due to the high read coverage obtained, which enabled the detection of mutations with lower variant allele frequency than in the TCGA analysis. In the cases of KMT2A and KMT2D, the mutation frequencies were reported as zero by the TCGA but were found to be 12.2% and 33.1%, respectively, in this study. The KMT2A and KMT2D mutations have been reported in squamous NSCLC in the COSMIC database, 28 albeit at a lower frequency, suggesting that mutation detection in these genes is challenging and should be interpreted cautiously. None of the commonly mutated genes predicted superior OS or PFS outcomes with afatinib over erlotinib treatment.
In line with other studies, 13,15 we identified high levels of EGFR overexpression in the IHC cohort (n = 345) of the LUXLung 8 population. Previous analyses have indicated that EGFR overexpression can predict outcomes with first-generation EGFR-targeted tyrosine kinase inhibitors in EGFR wild-type NSCLC. 18 However, we found that the benefits of treatment with afatinib over erlotinib in the LUX-Lung 8 population were apparent regardless of EGFR expression levels or EGFR gene copy number. It seems, therefore, that the efficacy of afatinib in the LUX-Lung 8 population is not driven by EGFR overexpression.
In addition to the emergence of afatinib as a second-line treatment option for lung SqCC, the immune checkpoint inhibitors nivolumab, pembrolizumab, and atezolizumab have been approved on the basis of the phase 3 studies CheckMate 017 (in lung SqCC), Keynote 010, and OAK (the latter 2 in NSCLC of any histology), respectively.
5-7 There is some evidence for PD-L1 as a predictive biomarker for these agents. For example, pembrolizumab is more active in patients with NSCLC tumors expressing high PD-L1 levels, 6 whereas nivolumab efficacy in CheckMate 017 appears to be independent of PD-L1 expression. 5 In other settings, nivolumab has demonstrated differential activity according to PD-L1 expression levels across different tumor types.
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Based on available data, checkpoint inhibitors are a secondline treatment option for lung SqCC. 30 However, treatment with afatinib may be a viable alternative among those patients for whom checkpoint inhibitors are unsuitable. Furthermore, given our findings, it will be interesting to assess checkpoint inhibitors in tumors with ERBB family mutations. It may be that afatinib represents a preferable treatment option for these patients.
Limitations
Although the biomarker data presented herein are extensive, the present study has a number of limitations. First, because of the retrospective nature of the analysis and the lack of statistically significant findings (with the exception of outcomes among patients with HER2 mutations), the results should be considered hypothesis generating rather than hypothesis testing. Second, TGA is limited in the ability to detect functional aberrations (eg, hypermethylation and phosphorylation), which may be key to differential efficacy. Third, only a minority of patients from the overall LUX-Lung 8 population could be included in tumor genetic and IHC analyses. As such, it is difficult to extrapolate the results to the overall LUX-Lung 8 population given that the subgroups were relatively small and subject to selection bias. Indeed, the TGA cohort was enriched for patients with PFS of 2 or more months; consequently, the OS and PFS benefit with afatinib over erlotinib treatment was greater than that observed in the overall LUX-Lung 8 data set. Finally, we do not present independent evidence for the activating role of the individual ERBB mutations or for their sensitization of the tumors to afatinib. 
Conclusions
Treatment with afatinib showed better outcomes than that with erlotinib across patient subgroups in this secondary analysis of the LUX-Lung 8 trial. The PFS and OS benefit with afatinib over erlotinib treatment was more pronounced among patients with ERBB mutation-positive tumors than among those without, especially among patients with tumors having HER2 or HER4 mutations. We hypothesize that the additional benefit with afatinib is attributable to its broad, irreversible inhibition of the entire ERBB signaling network. Finally, afatinib is a second-line treatment option for lung SqCC and may be particularly suitable for patients whose tumors carry at least 1 ERBB mutation. bypassed patients with squamous cell cancers. Identification of new treatable oncogenic drivers has predominately been confined to the nonsquamous subset, or more specifically, adenocarcinoma. The favorable results of tyrosine kinase inhibitor (TKI) therapy among patients whose cancers exhibit these anomalies (eg, alterations in EGFR, ALK, ROS1, BRAF, MET,orRET)hav eresulted in their inclusion in current guidelines for molecular testing and regulatory approval for associated therapies in most of these genomic subsets.
1 By comparison, no substantial progress has been made in the clinical application of targeted therapy for patients with squamous cancers during this same time, despite the discovery of a number of potential molecular targets and the initiation of associated clinical trials. 2 For example, potentially actionable abnormalities in phosphoinositide 3-kinase (PI3K), cyclin-dependent kinases (CDK) 4/6, and fibroblast growth factor receptor (FGFR) were present in 8%, 19%, and 16% of squamous lung cancers, respectively, in patients screened for the Lung-MAP (S1400) master protocol in advanced squamous lung cancer. Unfortunately, the recently completed Lung-MAP genotype-directed substudies on each of these 3 targets, S1400B (PI3K-directed TKI), S1400C (CDK 4/6-directed TKI), and S1400D (FGFR-directed TKI), failed to reach predetermined efficacy endpoints, with response rates of only 4%, 6%, and 7% and median overall survival of 5.9, 7.2, and 7.5 months, respectively.
3-5
Thus, the study by Goss et al 6 in this issue of JAMA Oncology identifying ERBB family mutations as potential oncogenic drivers in squamous lung cancer is timely. The study design of the LUX-Lung 8 trial is particularly applicable to this analysis because it directly compares treatment with the pan-ERBB inhibitor afatinib dimaleate to that with the EGFR-only inhibitor erlotinib hydrochloride among patients with squamous cancers, in whom EGFR-sensitizing mutations are rare. 7 As assessed by next-generation sequencing, ERBB family mutations were detected in tumors from 53 of 245 patients (21.6%), an unexpectedly high prevalence in squamous lung cancers. Only 16 of these tumors (6.5%) were EGFRsensitizing mutations. Although the benefits of treatment with afatinib in the previously reported intent-to-treat population were modest for both progression-free survival (PFS) and overall survival (OS), the analysis by Goss et al 6 reveals that efficacy was magnified among afatinib-treated patients with underlying ERBB mutations vs those without, an effect not observed among the corresponding erlotinib-treated cohorts. The differential efficacy in favor of treatment with afatinib was particularly notable among those patients with HER2 
